Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $348,330.59 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 7,879 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the sale, the chief operating officer now owns 18,672 shares in the company, valued at approximately $825,489.12. This trade represents a 29.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Monday, February 3rd, Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total value of $126,673.94.
• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Trading Down 1.8 %

MIRM traded down $0.85 during midday trading on Friday, reaching $47.02. 896,068 shares of the company were exchanged, compared to its average volume of 512,980. The stock has a market capitalization of $2.30 billion, a P/E ratio of -23.28 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $54.23. The stock's 50-day simple moving average is $47.89 and its 200 day simple moving average is $43.70. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Remove Ads

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $28,913,000. Loomis Sayles & Co. L P acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter worth approximately $19,473,000. State Street Corp raised its holdings in Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company's stock worth $69,955,000 after buying an additional 297,511 shares during the period. Erste Asset Management GmbH bought a new position in Mirum Pharmaceuticals in the third quarter valued at approximately $10,136,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $10,611,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.